BioLineRx Announces Worldwide Licensing Agreementfor BL-9020 for Treatment of Type 1 Diabetes
October 23, 2013 at 07:12 AM EDT
BioLineRx (NASDAQ: BLRX ) announced today that it has signed a worldwide, exclusive license agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, B.G. Negev Technologies and Applications Ltd., and Hadasit Medical Research Services and Development Ltd. for BioLineRx to develop and commercialize BL-9020, for the
